Home
    Disclaimer
    ← Back to 5-MeO-DiPT
    5-MeO-DiPT molecular structure

    5-MeO-DiPT Stats & Data

    Psychedelic Stimulant Empathogen Research-chemical
    Foxy Foxy methoxy foxy-methoxy 5meodipt
    Chemical Class Tryptamine
    Psychoactive Class Psychedelic / Stimulant

    Pharmacology

    DrugBank
    State Solid

    Description

    5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine, N,N-diethyltryptamine, bufotenine, psilocybin and psilocin. Since 1999, there has been a growing popularity of 5-MeO-DIPT among drug abusers. This substance is abused for its hallucinogenic effects.

    Pharmacodynamics

    5-methoxy-diisopropyltryptamine, also known as 5-methoxy-N,N-diisopropyltryptamine, 5-MeO-DiPT, foxy methoxy, or just foxy, is a tryptamine that is used recreationally as a psychedelic. 5-MeO-DiPT is orally active, and dosages between 6–20 mg are commonly reported. Many users note an unpleasant body load accompanies higher dosages. 5-MeO-DiPT is also taken by insufflation, or sometimes it is smoked or injected. Some users also report sound distortion, also noted with the related drug, DiPT.

    Absorption

    5-MeO-DIPT produces effects with an onset of 20 to 30 minutes and with peak effects occurring between 1 to 1.5 hours after administration.

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT1A receptor agonist (strongest binding affinity)
    Inhibitors
    weak serotonin reuptake inhibitor
    Other
    possible monoamine oxidase inhibition

    History & Culture

    5-MeO-DiPT was first synthesized and tested by American chemist Alexander Shulgin, who conducted the initial human trials of the compound in 1975. Shulgin subsequently co-authored a paper with M. F. Carter detailing the synthesis and human psychopharmacology of both 5-MeO-DiPT and its parent compound diisopropyltryptamine (DiPT), which was published in 1980. A more comprehensive summary of the synthesis procedure and extensive reports of human use later appeared in Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved). The compound first appeared as a novel designer drug in 1999, emerging in recreational drug markets where it gained the street name "Foxy" or "Foxy Methoxy." It has been used recreationally as a party drug and is noted for its reported aphrodisiac and tactile-enhancing properties. The substance has seen particular use in chemsex contexts, with notable prevalence among gay men and transgender women seeking its reputed sexual enhancement effects.

    Effect Profile

    Curated + 326 Reports
    Psychedelic 8.4

    Strong visuals, auditory effects, body load, and headspace

    Visual Intensity×3
    10102.6
    Headspace Depth×3
    96.62.3
    Auditory Effects×1
    10102.8
    Body Load / Somatic Effects×1
    10105.5
    Catalog Erowid BlueLight
    Empathogen 8.3

    Strong euphoria, stimulation, and sensory enhancement with moderate empathy

    Empathy / Social Openness×3
    65.31.5
    Euphoria / Mood Elevation×2
    107.34.5
    Stimulation×1
    107.05.2
    Sensory Enhancement×1
    10103.9
    Catalog Erowid BlueLight
    Stimulant 5.9

    Strong anxiety/jitters and euphoria with moderate stimulation, mild focus

    Stimulation / Energy×3
    78.0
    Euphoria / Mood Lift×2
    95.7
    Focus / Productivity×2
    45.8
    Anxiety / Jitters×1
    108.9
    Catalog Erowid
    Based on reports from:
    TiHKAL TiHKAL #37: 5-MeO-DIPT Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 5-MeO-DiPT

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    19-40 minutes
    30 minutes - 1.0 hours
    1-2 hours
    2-4 hours
    2-6 hours
    Total: 6-12 hours
    Insufflated
    4-19 minutes
    15-30 minutes
    45 minutes - 1.5 hours
    1-3 hours
    2-4 hours
    Total: 4-8 hours
    Smoked
    1-4 minutes
    4-10 minutes
    30 minutes - 1.5 hours
    1-2 hours
    2-6 hours
    Total: 4-8 hours

    Empirical Duration

    Erowid Reports
    Onset Come Up Peak Offset
    Oral (39 reports)

    Community Effects

    TripSit
    Positive
    euphoria body high music enhancement
    Negative
    nausea body load tachycardia

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    80% ●○○
    Psilocybin
    85% ●○○
    Psilocin
    85% ●○○
    Mescaline
    65% ●○○
    DMT
    85% ●○○
    5-MeO-DMT
    85% ●○○
    2C-B
    65% ●○○
    2C-E
    65% ●○○

    Experience Report Analysis

    Erowid BlueLight
    267 Reports
    1998–2023 Date Range
    19 With Age Data
    32 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 317 experience reports (267 Erowid + 59 Bluelight)

    317 Reports
    156 Effects Detected
    64 Positive
    61 Adverse
    31 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 64

    Color Enhancement 47.3% 85%
    Stimulation 44.1% 82%
    Music Enhancement 43.2% 85%
    Euphoria 38.8% 86%
    Tactile Enhancement 36.9% 86%
    Libido Enhancement 28.0% 86%
    Body High 27.4% 86%
    Focus Enhancement 24.9% 80%
    Patterning 24.0% 84%
    Joy 24.0% 86%
    Empathy 23.4% 78%
    Surface Breathing 20.0% 82%
    Visual Trails 20.0% 84%
    Introspection 18.0% 82%
    Awe 16.0% 84%
    Sociability Enhancement 16.0% 84%
    Orgasm Enhancement 14.0% 86%
    Insight 14.0% 76%
    Melting/flowing 14.0% 83%
    Contentment 12.0% 82%

    Adverse Effects 61

    Body Load 50.0% 86%
    Nausea 37.9% 81%
    Anxiety 36.3% 84%
    Tremor 32.0% 82%
    Muscle Tension 27.8% 88%
    Confusion 25.6% 84%
    Focus Suppression 18.0% 77%
    Depersonalization 16.0% 81%
    Fear 16.0% 86%
    Insomnia 16.0% 77%
    Thought Loops 14.0% 79%
    Restlessness 14.0% 82%
    Thought Disorganization 14.0% 80%
    Heaviness 10.0% 82%
    Stomach Cramps 10.0% 76%
    Thought Acceleration 10.0% 81%
    Vomiting 10.0% 82%
    Vibrating 10.0% 84%
    Jaw Clenching 9.8% 81%
    Headache 8.5% 76%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    Oral

    View data table
    Effect Light (n=33) Common (n=62) Strong (n=24) Heavy (n=38)
    Visual Distortions 63.6% 80.6% 75.0% 89.5%
    Music Enhancement 45.5% 69.4% 62.5% 26.3%
    Euphoria 57.6% 37.1% 41.7% 34.2%
    Anxiety 39.4% 30.6% 54.2% 55.3%
    Stimulation 54.5% 48.4% 41.7% 39.5%
    Empathy 30.3% 24.2% 54.2% 21.1%
    Color Enhancement 51.5% 48.4% 50.0% 44.7%
    Auditory Effects 51.5% 35.5% 50.0% 31.6%
    Tactile Enhancement 39.4% 40.3% 50.0% 31.6%
    Muscle Tension 48.5% 32.3% 37.5% 18.4%
    Nausea 33.3% 32.3% 41.7% 39.5%
    Focus Enhancement 30.3% 40.3% 12.5% 23.7%
    Confusion 18.2% 29.0% 33.3% 39.5%
    Hospital 9.1% 8.1% 12.5% 31.6%
    Introspection 30.3% 19.4% 25.0% 7.9%

    Insufflated

    View data table
    Effect Threshold (n=12)
    Visual Distortions 83.3%
    Stimulation 66.7%
    Closed-Eye Visuals 41.7%
    Muscle Tension 41.7%
    Empathy 33.3%
    Body High 33.3%
    Tactile Enhancement 33.3%
    Color Enhancement 33.3%
    Music Enhancement 33.3%
    Focus Enhancement 33.3%
    Nausea 33.3%
    Sedation 25.0%
    Confusion 25.0%
    Introspection 25.0%
    Time Distortion 25.0%

    Subjective Effect Ontology

    Experience Reports

    Structured effect tags extracted from 326 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

    Auditory

    music enhancement 137 42.7%

    Emotional

    euphoria 123 38.9% anxiety 115 36.0%

    Gastrointestinal

    nausea 120 38.0%

    Motor

    stimulation 140 43.8%

    Tactile

    tactile enhancement 117 36.5%

    Visual

    visual distortions 205 63.3% color enhancement 150 47.2%

    8 unique effects extracted · Derived from Erowid & Bluelight reports

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 267 experience reports.

    Insufflated dose range: 3.0–13.0 mg (median 10.0 mg)
    Effect Threshold (n=12)
    visual distortions
    83%
    stimulation
    67%
    closed-eye visuals
    42%
    muscle tension
    42%
    empathy
    33%
    body high
    33%
    tactile enhancement
    33%
    color enhancement
    33%
    music enhancement
    33%
    focus enhancement
    33%
    nausea
    33%
    sedation
    25%
    confusion
    25%
    introspection
    25%
    time distortion
    25%
    euphoria
    25%
    jaw clenching
    17%
    open-eye visuals
    17%
    anxiety
    17%
    Oral dose range: 10.0–18.0 mg (median 12.0 mg)
    Effect Light (n=33) Common (n=62) Strong (n=24) Heavy (n=38)
    visual distortions
    64%
    81%
    75%
    90%
    		↑
    music enhancement
    46%
    69%
    62%
    26%
    		↓
    euphoria
    58%
    37%
    42%
    34%
    		↓
    anxiety
    39%
    31%
    54%
    55%
    		↑
    stimulation
    54%
    48%
    42%
    40%
    		↓
    empathy
    30%
    24%
    54%
    21%
    		↓
    color enhancement
    52%
    48%
    50%
    45%
    		→
    auditory effects
    52%
    36%
    50%
    32%
    		↓
    tactile enhancement
    39%
    40%
    50%
    32%
    		↓
    muscle tension
    48%
    32%
    38%
    18%
    		↓
    nausea
    33%
    32%
    42%
    40%
    		↑
    focus enhancement
    30%
    40%
    12%
    24%
    		↓
    confusion
    18%
    29%
    33%
    40%
    		↑
    hospital
    9%
    8%
    12%
    32%
    		↑
    introspection
    30%
    19%
    25%
    8%
    		↓
    body high
    30%
    24%
    29%
    29%
    		→
    sedation
    27%
    18%
    29%
    24%
    		→
    closed-eye visuals
    15%
    21%
    25%
    5%
    		↓
    headache
    12%
    6%
    21%
    		— ↑
    dissociation
    15%
    19%
    12%
    16%
    		→

    Showing top 20 of 32 effects

    Risk Escalation

    Sentiment Analysis

    Average frequency of positive vs adverse effects across dose tiers (Oral)

    Light n=33
    10 positive 37.6% 9 adverse 21.9%
    Common n=62
    10 positive 35.5% 11 adverse 16.0%
    Strong n=24
    9 positive 40.8% 9 adverse 26.4%
    Heavy n=38
    10 positive 26.6% 11 adverse 20.8%
    View effect breakdown

    Adverse Effects

    Effect Light (n=33) Common (n=62) Strong (n=24) Heavy (n=38) Change
    Anxiety
    39%
    31%
    54%
    55%
    		+40%
    Muscle Tension
    48%
    32%
    38%
    18%
    		-62%
    Nausea
    33%
    32%
    42%
    40%
    		+18%
    Confusion
    18%
    29%
    33%
    40%
    		+117%
    Headache
    12%
    6%
    21%
    		— +71%
    Memory Suppression —
    6%
    		—
    18%
    		+183%
    Psychosis — —
    12%
    18%
    		+47%
    Sweating
    6%
    5%
    17%
    10%
    		+72%
    Jaw Clenching
    15%
    14%
    		— — -4%
    Motor Impairment —
    6%
    12%
    5%
    		-18%
    Increased Heart Rate
    12%
    6%
    8%
    10%
    		-13%
    Pupil Dilation
    12%
    6%
    		—
    8%
    		-34%
    Seizure — — —
    5%
    		0%

    Positive Effects

    Effect Light (n=33) Common (n=62) Strong (n=24) Heavy (n=38) Change
    Music Enhancement
    46%
    69%
    62%
    26%
    		-42%
    Euphoria
    58%
    37%
    42%
    34%
    		-40%
    Stimulation
    54%
    48%
    42%
    40%
    		-27%
    Empathy
    30%
    24%
    54%
    21%
    		-30%
    Color Enhancement
    52%
    48%
    50%
    45%
    		-13%
    Tactile Enhancement
    39%
    40%
    50%
    32%
    		-19%
    Focus Enhancement
    30%
    40%
    12%
    24%
    		-21%
    Introspection
    30%
    19%
    25%
    8%
    		-73%
    Body High
    30%
    24%
    29%
    29%
    		-4%
    Creativity Enhancement
    6%
    3%
    		—
    8%
    		+29%

    Dosage Distribution

    Dose distribution from experience reports

    Oral

    Median: 12.0 mg IQR: 10.0–18.0 mg n=151

    Insufflated

    Median: 10.0 mg IQR: 3.0–13.0 mg n=13

    Real-World Dose Distribution

    62K Doses

    From 361 individual dose entries

    Oral (n=265)

    Median: 12.0mg 25th: 9.0mg 75th: 16.0mg 90th: 24.6mg
    mg/kg median: 0.17 mg/kg 75th: 0.266

    Insufflated (n=39)

    Median: 7.0mg 25th: 3.0mg 75th: 10.0mg 90th: 13.4mg
    mg/kg median: 0.101 mg/kg 75th: 0.17

    Smoked (n=9)

    Median: 8.0mg 25th: 5.0mg 75th: 11.0mg 90th: 21.0mg
    mg/kg median: 0.143 mg/kg 75th: 0.23

    Intravenous (n=5)

    Median: 5.0mg 25th: 5.0mg 75th: 5.0mg 90th: 5.0mg
    mg/kg median: 0.067 mg/kg 75th: 0.079

    Intramuscular (n=6)

    Median: 2.0mg 25th: 2.0mg 75th: 3.5mg 90th: 4.0mg
    mg/kg median: 0.026 mg/kg 75th: 0.046

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Oral

    Median: 0.176 mg/kg IQR: 0.127–0.261 mg/kg n=140

    Insufflated

    Median: 0.092 mg/kg IQR: 0.051–0.169 mg/kg n=13

    Redose Patterns

    Redosing behavior across 210 reports

    18.1% Redosed
    1.3 Avg Doses
    31m Median Interval
    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Brazil Illegal Listed on Portaria SVS/MS nº 344. Possession, production, and sale are prohibited under national health surveillance regulations.
    Canada Unscheduled Not listed in Canada's schedules of controlled substances under the Controlled Drugs and Substances Act (CDSA) as of available documentation.
    China Category I psychotropic substance Controlled substance as of October 2015. Sale, purchase, import, export, and manufacture are prohibited under SFDA regulations.
    Denmark Illegal Controlled since February 20, 2004. Possession outside of licensed research and medical contexts is prohibited.
    Finland Illegal Banned in December 2014 under government regulations that prohibited over 100 psychoactive substances.
    Germany Anlage I BtMG Listed in Schedule I of the Betäubungsmittelgesetz (Narcotics Act) since October 10, 2000. Manufacturing, possession, import, export, purchase, sale, and dispensing without license are prohibited.
    Greece Controlled substance Designated a controlled substance on February 18, 2003 under national drug control legislation.
    Japan Controlled substance Prohibited since April 17, 2005 under Japanese drug control laws.
    Latvia Illegal Classified as a controlled substance under Latvian national drug legislation.
    New Zealand Class C (analogue) May be treated as a Class C controlled drug under analogue provisions due to structural similarity to DMT.
    Singapore Class A Controlled as a Class A substance since early 2006. Trafficking penalties include imprisonment ranging from 5 to 20 years and caning.
    Sweden Illegal (health hazard) Classified as a 'health hazard' under Lagen om förbud mot vissa hälsofarliga varor since October 1, 2004 via regulation SFS 2004:696. Sale and possession are prohibited.
    Switzerland Controlled (Verzeichnis E) Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics regulations.
    United Kingdom Class A Controlled under the Misuse of Drugs Act 1971 as an ether of 5-HO-DiPT, which falls under the tryptamine catch-all clause. Class A substances carry the most severe penalties.
    United States Schedule I Emergency scheduled by the DEA on April 4, 2003, then formally placed into Schedule I of the Controlled Substances Act on September 29, 2004. Manufacturing, possession, buying, selling, and distribution require a DEA license.

    References

    Data Sources

    Cited References

    ← Back to 5-MeO-DiPT